UK Safety Commissioner Calls for Urgent Compensation for Mesh Scandal Victims
Dr. Henrietta Hughes urges government action as women affected by pelvic mesh implants await financial redress.
Dr. Henrietta Hughes, the Patient Safety Commissioner for the UK, has expressed disappointment over the government's lack of action regarding financial compensation for women adversely affected by the pelvic mesh scandal.
In a statement reflecting on the past year, Dr. Hughes highlighted that many women have had their lives irreparably damaged by the use of transvaginal mesh implants, which were utilized to treat conditions such as pelvic organ prolapse and incontinence, following childbirth.
In her report released last year, Dr. Hughes asserted that there was a clear case for redress for thousands of women and children impacted by the scandal, as well as by the use of sodium valproate, a medication linked to serious adverse effects.
Dr. Hughes advocated for a two-stage financial redress scheme to address the grievances of affected individuals, including both an interim scheme and a more comprehensive main scheme.
“It is very disappointing that women who have suffered so much harm are still waiting for redress,” said Dr. Hughes.
“This is an injustice as it augments the original harm they suffered.
They need redress now, and the government must act immediately.”
Campaigners have echoed these sentiments, reporting a sense of silence and inaction from the government since the publication of the Hughes Report.
Kath Sansom, founder of the Sling the Mesh campaign group, stated that lives have been 'irreparably damaged' and that many affected women are unable to work or have been forced to reduce their hours due to chronic pain and disability.
In remarks made to the PA news agency, Ms. Sansom lamented the lack of a compensation scheme, asserting, “The time for excuses is over – we need action now.” She termed it unacceptable that the government continues to neglect the plight of women who have lost their health, jobs, and quality of life through no fault of their own.
The chairwoman of the All-Party Parliamentary Group for First Do Harm, MP Sharon Hodgson, reiterated the call for a response from the government, stressing that it has been over a year since the Hughes Report was published without any significant progress.
Hodgson emphasized the urgent need for recognition of the harms suffered by these women, stating that while financial compensation cannot reverse the damage, it would serve as acknowledgment of their grievances.
Alison Fuller from Epilepsy Action noted the struggles faced by families affected by sodium valproate and emphasized the importance of providing redress options.
The Department of Health and Social Care has acknowledged the complexities involved in addressing these issues and has committed to updating the Patient Safety Commissioner at the earliest opportunity.
A spokesperson for the Department stated, “The harm caused by sodium valproate and pelvic mesh continues to be felt today.
Our sympathies are with those affected, and we are fully focused on how best to support patients and prevent future harm.” The ongoing situation underscores a significant public health issue regarding the accountability of medical interventions and the treatment of patients in the UK.
In a statement reflecting on the past year, Dr. Hughes highlighted that many women have had their lives irreparably damaged by the use of transvaginal mesh implants, which were utilized to treat conditions such as pelvic organ prolapse and incontinence, following childbirth.
In her report released last year, Dr. Hughes asserted that there was a clear case for redress for thousands of women and children impacted by the scandal, as well as by the use of sodium valproate, a medication linked to serious adverse effects.
Dr. Hughes advocated for a two-stage financial redress scheme to address the grievances of affected individuals, including both an interim scheme and a more comprehensive main scheme.
“It is very disappointing that women who have suffered so much harm are still waiting for redress,” said Dr. Hughes.
“This is an injustice as it augments the original harm they suffered.
They need redress now, and the government must act immediately.”
Campaigners have echoed these sentiments, reporting a sense of silence and inaction from the government since the publication of the Hughes Report.
Kath Sansom, founder of the Sling the Mesh campaign group, stated that lives have been 'irreparably damaged' and that many affected women are unable to work or have been forced to reduce their hours due to chronic pain and disability.
In remarks made to the PA news agency, Ms. Sansom lamented the lack of a compensation scheme, asserting, “The time for excuses is over – we need action now.” She termed it unacceptable that the government continues to neglect the plight of women who have lost their health, jobs, and quality of life through no fault of their own.
The chairwoman of the All-Party Parliamentary Group for First Do Harm, MP Sharon Hodgson, reiterated the call for a response from the government, stressing that it has been over a year since the Hughes Report was published without any significant progress.
Hodgson emphasized the urgent need for recognition of the harms suffered by these women, stating that while financial compensation cannot reverse the damage, it would serve as acknowledgment of their grievances.
Alison Fuller from Epilepsy Action noted the struggles faced by families affected by sodium valproate and emphasized the importance of providing redress options.
The Department of Health and Social Care has acknowledged the complexities involved in addressing these issues and has committed to updating the Patient Safety Commissioner at the earliest opportunity.
A spokesperson for the Department stated, “The harm caused by sodium valproate and pelvic mesh continues to be felt today.
Our sympathies are with those affected, and we are fully focused on how best to support patients and prevent future harm.” The ongoing situation underscores a significant public health issue regarding the accountability of medical interventions and the treatment of patients in the UK.
